FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Kihara James 2. Date of Event Requiring Statement (MM/DD/YYYY)
6/23/2020 

3. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]
(Last)       (First)       (Middle)
C/O ACADIA PHARMACEUTICALS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Principal Accounting Officer /
(Street)
SAN DIEGO, CA 92130      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Employee Stock Option (Right to Buy)   (1) 4/6/2030  Common Stock  32302  $41.71  D   
Restricted Stock Units   (2)  (2) Common Stock  5955   (3) D   

Explanation of Responses:
(1)  25% of the shares subject to the Stock Option vest and become exercisable on April 7, 2021, and the remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
(2)  50% of the restricted stock units vest on April 7, 2022 and 25% vest on each of April 7, 2023 and April 7, 2024.
(3)  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Kihara James
C/O ACADIA PHARMACEUTICALS, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO, CA 92130


Principal Accounting Officer

Signatures
/s/ James K. Kihara 7/2/2020
**Signature of Reporting Person Date